The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market.
Mangoceuticals, Inc. (NASDAQ: MGRX) is one of the notable stock as the company continues to make strides in developing, marketing, and selling men's wellness products and services through its telemedicine platform. Its uniquely formulated drug, Mango remains the center of attention and a key driver of long-term prospects and underlying value. MGRX has been running an aggressive marketing campaign across the U.S. under the Make America Hard Again banner as it aims to target a broader market to unlock new revenue streams.
While the marketing campaign seeks to unlock new revenue-generating opportunities, it should also help MGRX collect valuable consumer data; which will underpin its future marketing efforts to target consumers through other health and wellness products. "Our newly launched Make America Hard Again campaign is more than just a new marketing concept--it's a mantra and a movement as our mission is to help men go hard in every aspect of their lives," stated MangoRx's Co-Founder and CEO, Jacob Cohen.
MGRX has recently announced its new collaboration with Ice Shaker to supply custom-made Mango-branded Ice Shaker bottles to be sold exclusively on the company's new MakeAmericaHardAgain.com e-commerce portal. Ice Shaker was founded by former NFL player, Chris Gronkowski in 2016 with a vision and mission to become a premium alternative to traditional, plastic shaker bottles. Read More at: https://finance.yahoo.com/news/mangoceuticals-collaborates-ice-shaker-launch-140000030.html
In addition to strengthening its web presence through the new banner, Mangoceuticals is also expanding its marketing drive through sponsorships on podcasts and platforms like Barstool Sports and Gas Digital Network. It's also seeking additional partnerships, sponsorships, and commercials through well-known nationwide platforms.
Mangoceuticals hopes to drive revenues for its core products and merchandise by adding new products to its telemedicine platform and flagship website. Amid the aggressive marketing campaigns to strengthen revenue streams, Mangoceuticals is also strengthening its product pipeline. It's fresh from releasing a second Mango product that leverages its existing custom compound. The new product should be available in the summer and is expected to open up a new revenue stream. The unveiling of the new product affirms MGRX's intention to establish Mango as a major player in this market.
Read More at: https://finance.yahoo.com/news/mangoceuticals-inc-announces-upcoming-launch-120000738.html
The men's health market has proven large enough to accommodate multiple competing products. The sector is ripe with attractive opportunities as it grows at a compound annual growth rate of 15% and MGRX seems to be at the right place at the right time. Read More at: https://www.bloomberg.com/press-releases/2022-08-11/men-s-health-market-size-share-growth-revenue-outlook-demand-and-market-is-expected-to-reach-highest-cagr-of-15-00-forecast.
Let’s take a look at how the stock has performed recently. MGRX last traded at $1.67 compared to a 52 week high of $4.37 suggesting huge upside potential for this NASDAQ listed stock. MGRX’s Co-Founder and CEO, Jacob Cohen, along with the MangoRx family, including Company officials and members of the executive management team, rang the Nasdaq Closing Bell on Thursday, May 18, 2023. Since then the company has been in news for all its recent advertisement deals including the launch of its “Some Things Are Better Hard” digital marketing campaign.
We strongly encourage you to check out their recent news at https://finance.yahoo.com/quote/MGRX/ and watch the video below for more information on MGRX
Video Link: https://www.youtube.com/embed/iKwg4nS8870
As always, conduct your own due diligence and follow traders vigilance.
Other companies in Mangoceuticals’s space includes: 111 (NASDAQ:YI), Rite Aid (NYSE:RAD), Walgreens Boots Alliance (NASDAQ:WBA), MedAvail Holdings (NASDAQ:MDVL) and China Jo-Jo Drugstores (NASDAQ:CJJD). Other notable biotech stocks include Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
Disclaimer: Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. A payment of $4,500 was received by InvestorBrandMedia.com from Bullyzeye Media LLC for content distribution on MGRX, from 06/12/2023 to 07/015/2023. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like "believes," "anticipates," "estimates," "expects," "projects," "intends," or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person's use of or access to this content.
Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/
